Epithelial splicing regulatory protein 1 (ESRP1) binds the FGFR-2 auxiliary cis-element ISE/ISS-3, located in the intron between exon IIIb and IIIc, and primarily promotes FGFR-2 IIIb expression. Here we assessed the role of ESRP1 in pancreatic ductal adenocarcinoma (PDAC). Immunohistochemical analysis was performed using anti-ESRP1, FGFR-2 IIIb and FGFR-2 IIIc antibodies in 123 PDAC cases. ESRP1 expression vector and small interference RNA (siRNA) targeting ESRP1 were transfected into human PDAC cells, and cell growth, migration and invasion were analyzed. In vivo heterotopic and orthotopic implantations using ESRP1 overexpression clones were performed and effects on pancreatic tumor volumes and hepatic and pulmonary metastases determined. ESRP1 immunoreactivity was strong in the nuclei of cancer cells in well-to-moderately differentiated PDACs but weak in poorly differentiated cancers. Well-to-moderately differentiated cancers also exhibited high FGFR-2 IIIb and low FGFR-2 IIIc expression, whereas this ratio was reversed in the poorly differentiated cancers. Increased ESRP1 expression was associated with longer survival in comparison with low ESRP1 expression, and PANC-1 cells engineered to express ESRP1 exhibited increased FGFR-2 IIIb expression and decreased migration and invasion in vitro, whereas ESRP1 siRNA-transfected KLM-1 cells exhibited increased FGFR-2 IIIc expression and increased cell growth, migration and invasion. In vivo, ESRP1-overexpressing clones formed significantly fewer liver metastases as compared with control clones. ESRP1 regulates the expression pattern of FGFR-2 isoforms, attenuates cell growth, migration, invasion and metastasis, and is a favorable prognostic factor in PDAC. Therefore, devising mechanisms to upregulate ESRP1 may exert a beneficial therapeutic effect in PDAC.
INTRODUCTION
Pancreatic ductal adenocarcinoma (PDAC) is associated with a dismal prognosis and 5-year survival rate of 6%. 1 A high percentage of PDAC overexpress a number of growth factors and their receptors, including fibroblast growth factor receptor 2 (FGFR-2). 2, 3 The FGFR-2 gene encodes several splice variants by alternative splicing. [4] [5] [6] FGFR-2 IIIb and FGFR-2 IIIc are representative FGFR-2 isoforms among several splice variants derived from FGFR-2. FGFR-2 IIIb and FGFR-2 IIIc are expressed predominantly in epithelial cells and mesenchymal cells, respectively, yet are almost identical to transmembrane-type receptors with extracellular immunoglobulinlike domains and cytoplasmic tyrosine-kinase domain. 7 However, FGFR-2 IIIb and FGFR-2 IIIc differ from each other in the carboxylterminal half of the third Ig-like region of the extracellular domain, as a consequence of alternative mRNA splicing. During epithelialto-mesenchymal transition (EMT) in bladder and prostate cancers, there is a switching in the expression of FGFR-2 IIIb to FGFR-2 IIIc. 8, 9 Both isoforms are expressed in PDAC, and there is a significant correlation between co-expression of FGFR-2 IIIb and FGF7, venous invasion, vascular endothelial growth factor (VEGF)-A expression and poor prognosis. 2 Moreover, PDAC cell growth is suppressed by targeting FGFR-2 IIIc with a small interfering RNA (siRNA) or with an anti-FGFR-2 IIIc antibody. 10 A number of auxiliary cis-elements and RNA-binding proteins that regulate splicing of FGFR-2 IIIb and FGFR-2 IIIc have been reported. 11, 12 Epithelial splicing regulatory protein 1 (ESRP1) is a RNA-binding protein that participates in the enhancement of splicing of the upstream exon IIIb while silencing the downstream exon IIIc binding intronic splicing enhancer/intronic splicing silencer-3 (ISE/ISS-3). 13 Furthermore, ESRP1 orchestrates an epithelial type of splicing regulatory program in EMT 14 by regulating the splicing of FGFR-2, CD44, ENAH and p120-catenin in breast, lung and colon cancer. 15, 16 Induction of EMT in normal human prostate epithelial cells by inducing knockdown of E-cadherin is also associated with the downregulation of both ESRP1 and ESRP2. 13, 17 Moreover, ectopic forced expression of the ESRP1 in mesenchymal cells is associated with changes in cell morphology and motility reminiscent of an epithelial phenotype, suggesting that splicing regulation drives critical aspects of EMTassociated phenotypic changes. 18 In the present study we sought to delineate the role of ESRP1 in PDAC and to assess the mechanisms whereby ESRP1 modulates EMT and the alternative splicing of FGFR-2.
RESULTS
Immunohistochemical analysis of ESRP1, FGFR-2 IIIb and FGFR-2 IIIc in human PDAC PDAC is often associated with regions that are moderately differentiated adenocarcinoma that form ductal-like structures, and with regions that are poorly differentiated and form alveolar or trabecular structures (Figure 1a ). ESRP1 was abundant in the nuclei of cancer cells that were well-to-moderately differentiated adenocarcinoma (Figure 1a , black arrows) but was weakly expressed in poorly differentiated adenocarcinoma (Figure 1a ). In serial tissue sections, strong expression of FGFR-2 IIIb was detected in the cytoplasm and/or cell membrane of well-tomoderately differentiated adenocarcinoma cells (Figure 1a , white arrows), whereas weak expression was seen in poorly differentiated adenocarcinoma. By contrast, FGFR-2 IIIc immunoreactivity was weak in well-to-moderately differentiated adenocarcinoma (Figure 1a ), and was strong in poorly differentiated adenocarcinoma (Figure 1a , arrowheads). Accordingly, cancer lesions were classified into two groups: well-to-moderately differentiated adenocarcinoma (well/mod) and poorly differentiated adenocarcinoma (poor), and evaluated for ESRP1, FGFR-2 IIIb and FGFR-2 IIIc immunoreactivity.
ESRP1 and FGFR-2 IIIb indices were significantly higher in well/ mod lesions than those in poorly differentiated lesions (Po0.01, Figure 1b and c). By contrast, FGFR-2 IIIc indices in poorly differentiated lesions were significantly higher than in well/mod lesions (Po0.05, Figure 1d ). In the normal human pancreas, ESRP1 immunoreactivity was detected in the nuclei and cytoplasm of acinar cells and in the nuclei of islet cells, but was either weak or undetectable in pancreatic ductal cells and absent in vascular endothelial cells ( Supplementary Figure 1 ).
Correlation of clinicopathological features with ESRP1 expression
To examine the correlation between ESRP1 expression and clinicopathological features, we divided 123 PDAC cases into two groups based on ESRP1 expression as determined by the median value for the immunohistochemical indices. The ESRP1high group (n ¼ 65) had more cases with histological grade of G1/ G2, whereas the ESRP1-low group (n ¼ 58) had more cases with G3 histology (P ¼ 0.04, Supplementary Table 1 ). By contrast, other clinicopathological factors such as age, sex, T, N and M factors, and stage based on UICC classification were similar in both groups. However, the overall survival rate of the ESRP1-high group was significantly longer than that of the ESRP1-low group (P ¼ 0.0189, Figure 1 . Immunohistochemical analysis of ESRP1, FGFR-2 IIIb and FGFR-2 IIIc in human pancreatic cancer tissues. (a) ESRP1 was strongly expressed in the nuclei of cancer cells in PDAC sections, especially in well-to-moderately differentiated adenocarcinoma forming ductal structure (arrows), whereas it was weakly expressed in poorly differentiated adenocarcinoma, which are characterized by trabecular or solid structure, but not ductal structure. In serial tissue sections, high ESRP1 expression was associated with stronger immunostaining for FGFR-2 IIIb (white arrows), whereas FGFR-2 IIIc immunoreactivity was increased in tumors with low ESRP1 levels (arrowheads). Upper panel, H&E staining; bar; 100 mm. (b and c) ESRP1 and FGFR-2 IIIb indices in well-/moderate-differentiated (well/mod) lesions were significantly higher than in poorly differentiated (poor) lesions (**Po0.01). (d) The FGFR-2 IIIc index was greater in poor lesions (*Po0.05).
Figure 2a
). The disease-free survival rate of the ESRP1-high group also tended to be longer than the ESRP1-low group (P ¼ 0.0767, Figure 2b ). Sixty-six patients received adjuvant chemotherapy ( Supplementary Table 1 ) with various combinations of gemcitabine, 5-fluorouracil (5-FU), tegafur-uracil (UFT) and TS-1 (consisting of tegafur, gimeracil and oteracil potassium). Excluding these patients and focusing on the surgery-only group, survival was not statistically better in the ESRP1-high group (Supplementary Figure 2 ).
Effects of transient transfection of an ESRP1-expressing vector in PANC-1 cells
To assess the role of ESPR1 in PDAC cells we initially characterized ESRP1 expression and determined that it was elevated in Capan-1, KLM-1, PK-1 and PK-8 cells, and low in PANC-1, PK-45H and MIA PaCa-2 cells (Supplementary Figure 3A) . FGFR-2 IIIb mRNA levels were also elevated in Capan-1, KLM-1, PK-1 and PK-8 cells, and low in the other cells (Supplementary Figure 3B) . In contrast, FGFR-2 IIIc mRNA levels were more variable, and were highest in PANC-1 cells (Supplementary Figure 3C) .
To examine the effects of increased ESRP1 expression we transiently transfected an ESRP1 expression vector into PANC-1 cells, as these cells expressed the lowest levels of endogenous ESRP1. Transfected cells (PANC-ESRP1) expressed high ESRP1 mRNA levels (Po0.01) by comparison with empty vectortransfected control cells (PANC-EV) or parental cells ( Figure 3a ). There was a concomitant increase in FGFR-2 IIIb mRNA levels in PANC-ESRP1 cells by comparison with PANC-EV and parental PANC-1 cells (Po0.05), whereas FGFR-2 IIIc levels were not altered ( Figure 3a ). Moreover, ESRP1 protein levels were increased in the nuclear fraction of PANC-ESRP1 cells (Figure 3b ). Phase-contrast microscopy did not reveal any characteristic morphological changes in these cells (Figure 3c , upper panels). Nonetheless, by immunofluorescence, ESRP1 was increased in the nuclei of PANC-ESRP1 cells as compared with parental and PANC-EV cells (Figure 3c , lower panels).
Effects of ESRP1-transfection on cell proliferation, migration and invasion in PANC-1 cells Similar growth rates were observed in PANC-1, PANC-EV and PANC-ESRP1 cells, as determined in a WST-8 cell counting assay ( Figure 4a ). By contrast, single-cell migration of PANC-ESRP1 cells was significantly decreased in comparison with parental PANC-1 and PANC-EV cells (Po0.01, Figure 4b ), and cell migration and invasion in a modified Boyden chamber assay were markedly decreased as compared with PANC-EV cells (Po0.01; Figure 4c and d).
To confirm the results observed following transient transfection, we established PANC-1 clones (-2 and -5) stably expressing ESRP1, and PANC-EV2 and PANC-EV9 clones expressing the empty vector (Supplementary Figure 4A ). Although FGFR-2 IIIb and IIIc levels were variable in each clone, the mRNA ratios of FGFR-2 IIIb to FGFR-2 IIIc were higher by comparison with the ratios in the respective control cells, but this difference was not statistically significant (Supplementary Figure 4A ). Phase-contrast microscopy did not reveal any morphological changes in the stably transfected clones (Supplementary Figure 4B , upper panels), whereas immunofluorescence revealed a marked increase in nuclear ESRP1 (Supplementary Figure 4B , lower panels). Importantly, ESRP1-2 and ESRP1-5 clones exhibited significantly attenuated single-cell movement and migration as compared with PANC-EV2 and -9 (Supplementary Figure 5A and B).
Effects of ESRP1 silencing on KLM-1 cell proliferation, migration and invasion
We next sought to determine the consequences of ESRP1 suppression on FGFR-2 IIIb and IIIc levels in KLM-1 cells, as these cells expressed the highest ESRP levels among our cell lines. Two siRNAs targeting different sites within the ESRP1 transcript (siESRP1-A and siESRP1-B) were used to silence ESRP1. A siRNA (siNeg) that does not bind to any human mRNA was used as a negative control. ESRP1 mRNA levels were decreased in siESRP1-A-and siESRP1-Bexpressing cells, FGFR-2 IIIb mRNA levels were not altered, whereas FGFR-2 IIIc mRNA levels were significantly increased (Po0.01) in comparison with siNeg cells (Supplementary Figure 6A ). Moreover, ESRP1 protein levels were markedly decreased in both the cytoplasmic (cyt) and nuclear (nu) fractions of siESRP1-A and siESRP1-B cells (Supplementary Figure 6B ), without any evident morphological changes (Supplementary Figure 6C , upper panels) but with a marked decrease in nuclear ESRP1 immunofluorescence (Supplementary Figure 6C , lower panels). As compared with siNeg cells, siESRP1-A and siESRP1-B cells also exhibited increased proliferation (Po0.05, Figure 5a ), as well as increased (Po0.01) migration ( Figure 5B ) and invasion ( Figure 5c ).
We previously reported that FGFR-2 IIIc is associated with enhanced proliferation, migration and invasion in pancreatic cancer cells. 10 To determine whether such increases were due to increased FGFR-2 IIIc expression, we performed double knockdown of ESRP1 and FGFR-2 IIIc in KLM-1 using ESPR1 siRNA and FGFR-2 IIIc siRNA (siESRP1-A þ siFGFR-2 IIIc and siESRP1-B þ siFGFR-2 IIIc). An irrelevant siRNA was used as a negative control (siESRP1-A þ siNeg and siESRP1-B þ siNeg). FGFR-2 IIIc mRNA levels were significantly higher (Po0.01) in siESRP1-A þ siNeg and siESRP1-B þ siNeg by comparison with parental or The disease-free survival rate of the high ESRP1 group tended to higher than that of the low ESRP1 group (P ¼ 0.0767).
siNeg cells, and were significantly decreased (Po0.01) by siESRP1-A þ siFGFR-2 IIIc or siESRP1-B þ siFGFR-2 IIIc (Supplementary Figure 7A ). Moreover, ESRP1 silencing with siESRP1-A or -B was associated with increased proliferation, migration and invasion, whereas in the presence of siFGFR-2 IIIc the cells were no longer growth-stimulated, and migration and invasion were inhibited (Supplementary Figure 7B -D). Thus, suppression of ESRP1 enhances FGFR-2 IIIc expression and promotes pancreatic cancer cell proliferation, migration and invasion, and these deleterious effects can be blocked by suppressing FGFR-2 IIIc expression.
Proteomic analysis of esrp1-transfected panc-1 cells ESRP1 has been reported to have important roles in ESRPregulated splicing network of hundreds of alternative splicing events within numerous genes with functions in cell-cell adhesion, polarity and migration. 19 To examine the proteins that are regulated by ESRP1, we performed two-dimensional electrophoresis using transient ESRP1 expression vector-transfected PANC-1 cells, and identified eight spots whose expression levels were altered at a twofold cutoff as compared with PANC-EV cells, and then identified these proteins using software. Transient Figure 8 ). Conversely, VCP, ENO1 and FLNA mRNAs were decreased in siESRP1expressing KLM-1 cells ( Supplementary Figure 9 ). These results were consistent with the data obtained by two-dimensional electrophoresis. Except for FLNA, there are no previous reports about splicing variants for these mRNA moieties. PCR analysis for the common site for FLNA and its splicing variant yielded similar results, leading us to conclude that ESRP1 did not regulate the splicing of FLNA.
We analyzed protein levels by immunoblotting in addition to analyzing the levels of differentially expressed proteins by proteomic analysis. Western blot analysis using anti-IQGAP1, FLNA and PLIN3 antibodies confirmed that ESRP1 modulated the levels of these proteins (Supplementary Figure 10) in parallel with the observed changes observed by mass spectrometry (Table 1) and at the mRNA level ( Supplementary Figure 8 ). With respect to 14-3-3e, the protein levels were only minimally decreased by ESRP1, but silencing ESRP1 in KLM-1 cells resulted in its upregulation (Supplementary Figure 10) . In contrast, the changes in vimentin, HSP 70, VCP and ENO1 were subtle and inconsistent. Thus, both proteins that were either most decreased or most increased by ESRP1 based on the proteomics analysis are most likely true RNA-binding targets for ESRP1. ESRP1 suppressed EMT induced by TGF-b in PANC-1 cell EMT is associated with enhanced cancer cell invasiveness, 20 and several of the proteins identified by two-dimensional TGF-b1 (20 ng/ml) induced morphological changes associated with EMT in PANC-1 cells and downregulated E-cadherin while upregulating vimentin in these cells at 24 and 48 h following its addition to the medium ( Supplementary Figures 11A and B) . When PANC-EV and PANC-ESRP1 cells were incubated with TGF-b1 (20 ng/ml) for 48 h, PANC-EV cells changed from cobblestonelike to spindle-shaped, whereas the morphology of PANC-ESRP1 cells was not altered (Supplementary Figure 11C) . Moreover, basal E-cadherin mRNA levels were higher in PANC-ESRP1 cells (Po0.05) than that in PANC-EV cells, and basal vimentin levels were lower in PANC-ESRP1 cells (Po0.01) than in PANC-EV cells ( Supplementary  Figures 11D and E) .
Effects of ESRP1 expression in PANC-1 and KLM-1 cells on additional receptors
To assess the generality of the effects of ESRP1, we next examined the consequences of its increased expression on the alternative splicing of FGFR-1, FGFR-3 and CD44 ( Supplementary  Figures 12A-C ). ESRP1 overexpression resulted in an increase in the ratio of FGFR-1 IIIb/IIIc by comparison with control cells, without altering FGFR-3 IIIb/IIIc or CD44s/CD44 ratios, whereas in ESRP1-suppressed KLM-1 cells, the ratios of FGFR-1 IIIb/IIIc and FGFR-3 IIIb/IIIc were significantly lower than in KLM-1 control cells, and the CD44s/ total CD44 ratio was significantly increased.
Effects of ESRP1 on orthotopic tumor formation and liver metastasis in NOG mice PANC-EV2 and PANC-EV9 cells and ESRP1-2 and ESRP1-5 cells readily formed tumors following subcutaneous implantation in nude mice. However, there were no significant differences in tumor growth between PANC-EV2 and PANC-EV9 cells and ESRP1-2 and ESRP1-5 cells over time ( Supplementary Figure 13) .
Small fragments from these tumors were then implanted orthotopically in the pancreas of NOG mice, yielding pancreatic tumors that tended to be smaller in volume and lighter in weight when derived from ESRP1-2 and ESRP1-5 cells by comparison with the PANC-EV-derived tumors, but these differences were not statistically significant (Figure 6a ). In contrast, the ESRP1-2 and Figure 6b ) and pulmonary metastases (Po0.01, Figure 6c ). Interestingly, most of the mice implanted orthotopically with PANC-EV cells exhibited marked weight loss and cachexia, and one mouse died. All the mice were killed at that point due to animal ethics considerations. At that time point, all of the ESRP1-implanted mice appeared healthy and in stable condition, and did not exhibit cachexia.
DISCUSSION
PDAC often arises from precursor lesions called pancreatic intraepithelial neoplasia (PanIN) that progress from low to high grade, to invasive and metastatic cancer. [21] [22] [23] Major driver mutations in PDAC include mutated Kras (99% incidence), p53 (70%), Smad4 (55%) and p16 (85%), overexpression of multiple tyrosine-kinase receptors and ligands and overexpression of TGF-bs. 24, 25 PDAC patients often exhibit distant metastases, especially to the liver and lung. 26 PDAC is also associated with overexpression of FGF ligands and an intense desmoplasia. 27, 28 Although the molecular mechanisms that modulate pancreatic cancer cell metastasis are not known, it is well established that the underlying processes are complex and multifactorial, and that the microenvironment, the immune system and both genetic and epigenetic alterations in cancer cells contribute to the metastatic process. [29] [30] [31] EMT represents an additional crucial mechanism for enhancing the ability of cancer cells to spread and metastasize. 20 Many of the alterations that are associated with EMT may be affected through a repertoire of alternative splicing events that are regulated by key splicing factors such as ESRP1. In the present study we determined that ESRP1 was abundant in well-to-moderately differentiated cancers that also expressed high FGFR-2 IIIb levels, but its expression was decreased in poorly differentiated cancers that expressed relatively high levels of FGFR-2 IIIc. These observations raise the possibility that increased ESRP1 levels lead to elevated levels of FGFR-2 IIIb and an epithelial rather than a mesenchymal phenotype that could reflect less aggressive disease. Five observations support this conclusion. First, elevated expression of ESRP1 was associated with prolonged survival. Second, PANC-1 cells engineered to express ESRP1 exhibited increased FGFR-2 IIIb expression and decreased migration and invasion in vitro. Third, ESRP1 blunted TGF-b-mediated induction of EMT. Fourth, silencing ESRP1 in KLM-1 cells was associated with increased FGFR-2 IIIc expression and increased cell growth, migration and invasion, and these changes were blocked by silencing FGFR-2 IIIc. Fifth, ESRP1overexpressing PANC-1 clones formed significantly fewer hepatic and pulmonary metastases as compared with control clones.
ESRP1 and ESRP2 act as central coordinators of an alternative splicing network that underlies EMT. 14, 19 In our study, increased ESRP1 expression changed cell morphology from spindle-shaped to cobblestone-like, prevented TGF-b1-induced morphological alterations that are associated with EMT and suppressed cancer cell invasion. These alterations have been correlated with a mesenchymal-to-epithelial transition process. 32 Moreover, high ESRP1 expression was associated with well-to-moderately differentiated lesions, low histological grades and improved survival. Together with the observation that ESRP1 repressed cell migration and invasion, our findings suggest that low ESRP1 levels contribute to enhanced EMT in PDAC.
Alternative splicing is now recognized to expand transcriptomic diversity, and nearly all multi-exon human genes undergo alternative splicing. 33, 34 Previous reports have shown that ESRP1 directly binds to the ISE/ISS-3 element of the FGFR-2 gene and induces expression of FGFR-2 IIIb. 13 In the present study, transient transfection of ESRP1 in PANC-1 cells increased FGFR-2 IIIb mRNA levels, without altering FGFR-2 IIIc expression, perhaps due to the existence of additional mechanisms that regulate FGFR-2 IIIc expression. However, stable transfection of ESRP1 in PANC-1 cells yielded clones that either did not change the expression of FGFR-2 IIIb or IIIc, or increased the expression of both receptors, underscoring the complexity of this splicing regulation. Nonetheless, in both clones, there was an increase in the ratio of FGFR-2 IIIb to FGFR-2 IIIc, and both clones exhibited decreased motility. The importance of ESPR1 in the modulation of FGFR-2 isoform expression is highlighted by our observation that suppression of ESRP1 in KLM-1 cells consistently increased FGFR-2 IIIc mRNA levels without altering FGFR-2 IIIb expression, revealing that a 50% decrease in endogenous ESRP1 levels increased FGFR-2 IIIc by twoto threefold. The biological significance of this increase is highlighted by the simultaneous knockdown of FGFR2IIIc and ESRP1 in KLM-1 cells, which demonstrated that the increases in proliferation, migration and invasion induced by ESRP1 were eliminated by concomitantly downregulating FGFR2IIIc expression.
Our results do not exclude the possibility that some of the observed biological effects in the present study could be due to ESRP1's ability to modulate the splicing of numerous additional mRNA moieties. To explore this possibility, we performed proteomic analysis using transiently ESRP1-transfected PANC-1 cells. Most of the proteins thus identified are involved in the modulation of cell proliferation, migration and invasion. Moreover, vimentin, has a well-known role in EMT. In addition, IQGAP1 is a large (189 kDa) scaffold protein that binds F-actin, helps promote cell migration, proliferation and tumorigenesis. 35 IQGAP1 also facilitates caveolae insertion into the plasma membrane, 36 thereby helping to promote EMT. 37 Similarly, 14-3-3e promotes invasion of gastric cancer cells and may promote EMT in these cells. 38 Thus, the ability of ESRP1 to suppress both IQGAP1 and 14-3-3e is consistent with its ability to suppress EMT. Recently, a splicingsensitive microarray platform was used to characterize ESRPregulated splicing regulatory networks and identified hundreds of novel ESRP-regulated splicing events but did not detect the candidate proteins identified and validated in our study. 19 Proteomic analysis revealed that ESRP1-transfected PANC-1 cells transiently transfected to express high ESRP1 levels exhibited decreased expression of vimentin, 14-3-3e, heat shock protein 70 and IQGAP1, and increased expression of valosin containing protein, a-enolase, filamin-a and perilipin 3.
Moreover, there are no previous reports of alternative splicing variants of these potential target proteins, except for filamin alpha, underscoring the novelty of our findings and raising the possibility that these types of splicing events are context-and cell-dependent. ESRP1 also modulated splicing of additional mRNA moieties in pancreatic cancer cells, as evidenced by our finding that its suppression resulted in alternative splicing of FGFR-1, FGFR-3 and CD44. CD44s has been implicated in promoting EMT 39 and its upregulation in KLM-1 cells following ESRP1 silencing further confirms that ESRP1 acts by modulating multiple splicing events to suppress pancreatic cancer cell metastasis. In agreement with these observations, ESRP1 binds to 5'UTR of mRNAs and causes alterations in protein levels of several cancer-related genes including c-myc, cyclin D1, p21, PKCa, integrin b and E-cadherin. 15 Taken together with our present findings, these observations suggest that ESRP1 exerts an important role in metastasissuppression in PDAC by modulating the expression of splice variants of many important mRNA moieties implicated in EMT. Given that EMT may lead to cancer cell dissemination from the pancreas even prior to tumor formation, 40, 41 devising mechanisms to upregulate ESRP1 may represent a novel chemopreventive and therapeutic approach for suppressing EMT and metastasis in PDAC.
MATERIALS AND METHODS Materials
The following were purchased from Abcam plc (Cambridge, MA, USA): anti-ESRP1, anti-lamin A þ C, anti-Perilipin 3 and anit-IQGAP1 antibodies; Figure 6 . Effects of ESRP1 on orthotopic tumor growth and metastasis in NOG mice. (a) Tumor growth. Pancreatic tumors derived from PANC-EV cells were larger (left panel) and heavier (right panel) than tumors derived from ESRP1-transfected cells, but these differences were not statistically significant (n ¼ 3 in each group). Bar: 10 mm. (b) Hepatic metastases. ESRP1-2 and ESRP1-5 cells exhibited fewer hepatic metastases by comparison with PANC-EV2 and -9 cells. Consequently, the percentage of human HLA class I positive cancer areas/total liver areas was markedly decreased in ESRP1-2 and ESRP1-5 tumors (**Po0.01). (c) Pulmonary metastases. ESRP1-2 and ESRP1-5 cells also exhibited a markedly decreased incidence of pulmonary metastases, as evidenced by the lower percentage of human HLA class I-positive cancer areas/ total liver areas in ESRP1-2 and ESRP1-5 derived tumors (**Po0.01). Bars: 10 mm and 0.1 mm in B; 5 mm and 0.2 mm in c.
anti-filamin A from Novus Biologicals (Littleton, CO, USA); anti-14-3-3e from Cell signaling technology (Boston, MA, USA); anti-CD31 antibody from AbD Serotec (Kidlington, UK); anti-cytokeratin (CK) 19 antibody from Boehringer Mannheim GmbH (Mannheim, Germany); anti-insulin antibody from DAKO JAPAN (Tokyo, Japan); anti-HLA class I-A, B, C antibody from Hokudo Co., Ltd. (Tokyo, Japan); Histofine Simple Stain MAX PO (M) and (R) kits from Nichirei (Tokyo, Japan); FastPure RNA kit and pBApo-CMV Neo DNA vector from Takara Bio Inc. (Tokyo, Japan); TaqMan Gene Expression Assays for ESRP1 (Hs00214472_m1), CD44s (Hs01081473_m1), CD44v (Hs00153304_m1), E-cadherin (Hs01012953_m1), Vimentin (Hs00185584_m1), HSP 70 (Hs03044880_gH), VCP (Hs00997642_m1), ENO1 (Hs00361415_m1), IQGAP1 (Hs00896595_m1), 14-3-3e (Hs00356749_g1) FLNA (Hs00924645_m1, Hs00926963_m1), PLIN3 (Hs00998416_m1), 18S rRNA (Hs99999901_s1) and siRNAs targeting human ESRP1 (s29571, 29572) and negative control siRNA (Silencer select Negative control #2) from Life Technologies Corporation (Carlsbad, CA, USA), We prepared two different types of TaqMan primers for filamin alpha: one is specific for a splicing variant and the other is for common site of native filamin alpha and its splicing isoforms; FuGene HD transfection reagent from Roche Diagnostics (Mannheim, Germany); TransIT-siQUEST Transfection Reagent from Mirus Bio LLC (Madison, WI, USA); NE-PER nuclear and cytoplasmic extraction reagent from Thermo Fisher Scientific (Waltham, MA, USA); WST-8 cell counting kit from Wako Pure Chemical Industries (Osaka, Japan); BioCoat Matrigel invasion chamber (8-mm pore size) from BD Bioscience (Franklin Lakes, NJ, USA); immobilized pH gradient (IPG, pH4-7) strips and Oriole Fluorescent Gel Stain Kit from Bio-Rad laboratories (Hercules, CA, USA); recombinant human ESRP1 (H00054845-P01) and recombinant human ESRP2 (H00080004-P01) from Novus Biologicals; recombinant human TGF-b1 from R&D Systems (Minneapolis, MN, USA); and L-column Micro from Chemicals Evaluation and Research Institute (Tokyo, Japan). All other reagents were purchased from Sigma-Aldrich Corporation (St Louis, MO, USA). Anti-human ESRP1&2 antibody was a kind gift from Dr Russ P Carstens (University of Pennsylvania School of Medicine, Philadelphia, PA, USA). 19 Human PDAC tissues One hundred and twenty three PDAC patients who participated in this study were receiving treatment at Nippon Medical School Hospital (Tokyo, Japan) from 1995 to 2011. The clinicopathological stage was determined according to the TNM classification system of the International Union Against Cancer (UICC). Normal pancreata were obtained from patients who underwent partial pancreatectomy due to the presence of a benign heterotopic spleen in the pancreas (n ¼ 8). This study was carried out in accordance with the principles embodied in the Declaration of Helsinki, 2008, and informed consent for the usage of pancreatic tissues was obtained from each patient.
Immunohistochemistry
Paraffin-embedded serial tissue sections (3.5-mm thick) were subjected to immunostaining using the Histofine Simple Stain Max PO kits. Rabbit polyclonal anti-FGFR-2 IIIb 2 and IIIc antibodies 10, 42 were prepared as previously reported. Sections were then incubated overnight with the appropriate antibody (1:50 for ESRP1, 1:500 for FGFR-2 IIIb, 1:250 for FGFR-2 IIIc, 1:50 for CD31, 1:100 for CK19 and 1:1000 for insulin). For the evaluation of the intensity and positive proportion of ESRP1, FGFR-2 IIIb and FGFR-2 IIIc immunostaining, the following scale was employed: 0, no staining; 1 þ , mild staining; 2 þ , moderate staining and 3 þ , intense staining: 0, no staining; 1 þ ,1-30%; 2 þ , 31-60%; 3 þ , 460%, positive proportion in cancer cells. 43 Pancreatic cancer cell lines PANC-1, MIA PaCa-2, KLM-1, PK-1, PK-8 and PK-45H, human PDAC cell lines were obtained from the Cell Resource Center for Biomedical Research, Institute of Development, Aging and Cancer, Tohoku University (Sendai, Japan), and Capan-1 cells were purchased from American Type Culture Collection (Manassas, VA, USA). Cell lines were authenticated by short tandem repeat profiling analysis (March 2012).
Quantitative RT-PCR (qRT-PCR)
qRT-PCR was performed with the StepOnePlus PCR system (Life Technologies Corporation) using specific primers and a TaqMan probe. 10 qRT-PCR results were expressed as the ratio of target to 18S rRNA, the latter serving as an internal standard. Gene expression levels were measured in triplicate.
Construction of ESRP1 and FGFR-2 IIIc expression vector, and generation of transiently and stably transfected cells
The full-length ESRP1 cDNA fragment was ligated into pBApo-CMV Neo DNA vector. The full-length FGFR2IIIc cDNA fragment was ligated to the 3 0 end of the human cytomegalovirus early promoter/enhancer in the eukaryotic expression vector pIRES2-EGFP. PANC-1 cells (1 Â 10 5 ) were transfected with 5 mg of DNA using FuGENE HD, and used in experiments 72 h later. To prepare stable transfected clones, cells were passaged and cultured with Geneticin (1000 mg/ml).
Transfection of siRNA targeting ESRP1 and FGFR-2 IIIc
We used two types of siRNA targeting different sites in ESRP1 mRNA: siESRP1-A and siESRP1-B. Sense ESRP1 siRNA sequences of siESRP1-A and siESRP1-B were 5 0 -CCUUCGAGGUCUUCCCUAU-3 0 , and 5 0 -GCAGCAAGAUGGA ACUUAU-3 0 , respectively. Each siRNA stock solution and TransIT-siQUEST were mixed in serum-free medium. In preliminary experiments, the optimal concentration of siRNAs targeting ESRP1 was determined to be 2.5 nM by qRT-PCR for ESRP1. The custom-designed siRNA against specific IIIc region of FGFR-2 IIIc were purchased, and the sense sequence was 5 0 -GUG-CUU-GGC-GGG-UAA-UCC-Utt-3 0 (s275291). The cells were plated at a density of 1 Â 10 5 cells in a 35-mm dish and transfected with 5 nM siRNAs for FGFR-2 IIIc. 10 Western blot analysis Cytoplasmic (cyt) and nuclear protein (nu) were separately extracted using the NE-PER extraction reagents. Lysates were subjected to SDS-PAGE using non-reducing conditions for the anti-ESRP1&2 antibodies, and reducing conditions for the other antibodies. The separated proteins were transferred to membranes, which were then incubated overnight with the anti-ESRP1&2 antibodies (1:1000 in dilution). Membranes were reblotted with a mouse anti-b-actin antibody (1:5000 in dilution) and anti-lamin A þ C antibody (1:1000 in dilution). The anti-ESRP1 antibody (Sigma) that was used in immunohistochemical and fluorescence staining was not suitable for western blotting. Therefore, we used an ESRP antibody for western blotting, which detected both ESRP1 and ESRP2. 13 Immunofluorescence staining Cells were fixed with 4% paraformaldehyde, incubated with 0.1% of Triton-X for 5 min, and overnight at 4 1C with the anti-ESRP1 antibody (1:100). Fluorescent images were observed under a Digital Eclipse C1 TE2000-E microscope (Nikon Instech Co., Ltd., Tokyo, Japan). 44 The confocal settings including laser power and detector sensitivity were unchanged during the acquisition of all images.
Cell proliferation assays
Cells were cultured in RPMI 1640 medium with 10% FBS at a density of 5 Â 10 3 in 96-well plates followed by incubation for 24, 48 or 72 h. Cells were then incubated with WST-8 cell counting reagent for 4 h. Optical density was measured using a plate reader (Bio-Rad Laboratory, Hercules, CA, USA) at 450 nm.
Single-cell movement assay
To assess cell migration, single-cell movement assay was performed. 10 Cells (5000 per well) were seeded onto four-well glass bottom dish. Cell movement was monitored for 24 h by a Digital Eclipse TE 2000-E motorized inverted microscope (Nikon Insteck Co., Ltd.). The total distance of individual cells covered within 24 h was determined using the Metamorph software 7.6 (Universal Imaging Corp. Ltd., Buckinghamshire, UK).
Boyden chamber assays
Migration and invasion assays were carried out using a modified Boyden chamber technique. The cells on the upper surface of the filter were carefully removed with a cotton swab, after 8 h for PANC-1 cells and after 20 h for KLM-1 cells, due to the slower migration of KLM-1 cells. These time points were selected based on preliminary data. 44 Cell numbers on each membrane were counted in five high-power fields ( Â 200). Cell invasion assays were performed using the matrigel coating inserts, and cell counting was performed as above.
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Two-dimensional electrophoresis and imaging
Two-dimensional gel electrophoresis was carried out by the method of Gorg et al. 45, 46 with modifications. First-dimension isoelectric focusing gel electrophoresis was carried out by using an electrophoresis apparatus from Nihon Eido (Tokyo, Japan) at 200 V for 30 min, at 400 V for 30 min, at 1,000 V for 1 h and at 2000 V for 15-16 h. Then, the two-dimensional SDS-PAGE was performed using a 10% acrylamide gel. After electrophoresis, the gels were stained with Oriole Fluorescent Gel Stain Kit. The gels were visualized using ChemiDoc XRS system (Bio-Rad, Hercules, CA, USA) and analyzed using PDQuest 2D-image-analysis software (Bio-Rad).
Protein identification using mass spectrometry
The protein spots were excised manually and then digested using In-gel Tryptic Digestion Kit according to the manufacturer's protocol. Liquid chromatography was performed using an Advance-nano UHPLC (AMR Inc., Tokyo, Japan). The eluents used were A: 0.1% formic acid in water and B: acetonitrile. Peptides generated by tryptic digestion were loaded onto a L-column Micro (C18, 3 mm, 0.1 Â 50 mm) and separated at a flow rate of 500 nl/min with the concentration gradient of acetonitrile from 5% B to 45% B in 30 min. Gradient-eluted peptides were analyzed using an amaZon ETD ion-trap mass spectrometer (Bruker Daltonics, Billerica, MA, USA). The data were acquired in a data-dependent manner, in which MS/MS fragmentation was performed on the 10 most intense peaks of every full MS scan. All MS/MS spectra data were searched against the SwissProt using Mascot (Matrix Science, London, UK).
Effects of TGF-b1 in ESRP1-overexpressing PANC-1 cells
The ESRP1 expression vector was transfected into PANC-1 cells, which were then incubated for 24 h. Recombinant human TGF-b1 (20 ng/ml) was then added to the incubation medium, and cells were incubated for 24 and 48 h. RNA samples were then extracted.
Heterotopic and orthotopic implantations of ESRP1-overexpressed PANC-1 cells in immunodeficient mice
Six-week-old male nude mice (BALB/cA Jcl-nu/nu; CLEA Japan Inc, Tokyo, Japan) were subcutaneously injected in the both flanks with 1 Â 10 6 PANC-EV2, PANC-EV9, ESRP1-2 and ESRP1-5 cells/mouse (n ¼ 3). Four weeks later, the subcutaneous tumors were excised. To evaluate tumor growth in an orthotopic model, we used NOD/Shi-scid, IL-2Rg null (NOG; Central Institute for Experimental Animals, Kanagawa, Japan) mice. 47 Tumor fragments from subcutaneous tumors (2 mm square) were sutured onto the surface of the tail of the pancreas of 6-week-old, male, NOG mice (n ¼ 3 per cell line). 10, 48 Animals were monitored for 5 weeks, and pancreatic tumors, lungs and livers were excised, weighed and processed for HLA class I immunostaining to mark cells that were of human origin. Quantitative morphometry was performed to determine the percent of HLA class I-positive cancer area/ total tissue area on five distinct areas, using WinROOF (Mitani Corporation, Fukui, Japan). 44 The experimental protocol was approved by the Animal Ethics Committee of Nippon Medical School.
Statistical analysis
All quantitative data were presented as mean ± s.e.m. values. Data for two groups were compared using Student's t-test. The data between multiple groups were compared using one-way ANOVA. The w 2 -test and Fisher's exact test were used to analyze the correlation between ESRP1-expression and clinicopathological features. Cumulative survival rate was calculated with the Kaplan-Meier method, and the significance of differences in survival rates was analyzed by the log-rank test. Po0.05 was considered as statistically significant. Computations were performed using the Stat View J version 5.0 software package (SAS Institute, Inc., Cary, NC, USA).
